Cargando…
Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate
Prostate biopsy is recommended in cases of positive magnetic resonance imaging (MRI), defined as Prostate Imaging Reporting and Data System (PIRADS) category ≥ 3. However, most men with positive MRIs will not be diagnosed with clinically significant prostate cancer (csPC). Our goal was to evaluate p...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820960/ https://www.ncbi.nlm.nih.gov/pubmed/36614957 http://dx.doi.org/10.3390/jcm12010156 |
_version_ | 1784865584578560000 |
---|---|
author | Szempliński, Stanisław Kamecki, Hubert Dębowska, Małgorzata Zagożdżon, Bartłomiej Mokrzyś, Mateusz Zawadzki, Marek Sosnowski, Roman Tokarczyk, Andrzej Poletajew, Sławomir Kryst, Piotr Nyk, Łukasz |
author_facet | Szempliński, Stanisław Kamecki, Hubert Dębowska, Małgorzata Zagożdżon, Bartłomiej Mokrzyś, Mateusz Zawadzki, Marek Sosnowski, Roman Tokarczyk, Andrzej Poletajew, Sławomir Kryst, Piotr Nyk, Łukasz |
author_sort | Szempliński, Stanisław |
collection | PubMed |
description | Prostate biopsy is recommended in cases of positive magnetic resonance imaging (MRI), defined as Prostate Imaging Reporting and Data System (PIRADS) category ≥ 3. However, most men with positive MRIs will not be diagnosed with clinically significant prostate cancer (csPC). Our goal was to evaluate pre-biopsy characteristics that influence the probability of a csPC diagnosis in these patients. We retrospectively analyzed 740 consecutive men with a positive MRI and no prior PC diagnosis who underwent MRI-ultrasound fusion biopsies of the prostate in three centers. csPC detection rates (CDRs) for each PIRADS category were calculated. Patient, disease, and lesion characteristics were studied for interdependencies with the csPC diagnosis. The CDR in patients with PIRADS categories 3, 4, and 5 was 10.5%, 30.7%, and 54.6%, respectively. On both uni- and multivariable regression models, older age, being biopsy-naïve, prostate specific antigen ≥ 10 ng/mL, smaller prostate volume, PIRADS > 3, a larger maximum lesion size, a lesion in the peripheral zone, and a positive digital rectal examination were associated with csPC. In this large, multicenter study, we provide new data regarding CDRs in particular PIRADS categories. In addition, we present several strong predictors that further alter the risk of csPC in MRI-positive patients. Our results could help in refining individual risk assessment, especially in PIRADS 3 patients, in whom the risk of csPC is substantially low. |
format | Online Article Text |
id | pubmed-9820960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98209602023-01-07 Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate Szempliński, Stanisław Kamecki, Hubert Dębowska, Małgorzata Zagożdżon, Bartłomiej Mokrzyś, Mateusz Zawadzki, Marek Sosnowski, Roman Tokarczyk, Andrzej Poletajew, Sławomir Kryst, Piotr Nyk, Łukasz J Clin Med Article Prostate biopsy is recommended in cases of positive magnetic resonance imaging (MRI), defined as Prostate Imaging Reporting and Data System (PIRADS) category ≥ 3. However, most men with positive MRIs will not be diagnosed with clinically significant prostate cancer (csPC). Our goal was to evaluate pre-biopsy characteristics that influence the probability of a csPC diagnosis in these patients. We retrospectively analyzed 740 consecutive men with a positive MRI and no prior PC diagnosis who underwent MRI-ultrasound fusion biopsies of the prostate in three centers. csPC detection rates (CDRs) for each PIRADS category were calculated. Patient, disease, and lesion characteristics were studied for interdependencies with the csPC diagnosis. The CDR in patients with PIRADS categories 3, 4, and 5 was 10.5%, 30.7%, and 54.6%, respectively. On both uni- and multivariable regression models, older age, being biopsy-naïve, prostate specific antigen ≥ 10 ng/mL, smaller prostate volume, PIRADS > 3, a larger maximum lesion size, a lesion in the peripheral zone, and a positive digital rectal examination were associated with csPC. In this large, multicenter study, we provide new data regarding CDRs in particular PIRADS categories. In addition, we present several strong predictors that further alter the risk of csPC in MRI-positive patients. Our results could help in refining individual risk assessment, especially in PIRADS 3 patients, in whom the risk of csPC is substantially low. MDPI 2022-12-25 /pmc/articles/PMC9820960/ /pubmed/36614957 http://dx.doi.org/10.3390/jcm12010156 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Szempliński, Stanisław Kamecki, Hubert Dębowska, Małgorzata Zagożdżon, Bartłomiej Mokrzyś, Mateusz Zawadzki, Marek Sosnowski, Roman Tokarczyk, Andrzej Poletajew, Sławomir Kryst, Piotr Nyk, Łukasz Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate |
title | Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate |
title_full | Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate |
title_fullStr | Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate |
title_full_unstemmed | Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate |
title_short | Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate |
title_sort | predictors of clinically significant prostate cancer in patients with pirads categories 3–5 undergoing magnetic resonance imaging-ultrasound fusion biopsy of the prostate |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820960/ https://www.ncbi.nlm.nih.gov/pubmed/36614957 http://dx.doi.org/10.3390/jcm12010156 |
work_keys_str_mv | AT szemplinskistanisław predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate AT kameckihubert predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate AT debowskamałgorzata predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate AT zagozdzonbartłomiej predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate AT mokrzysmateusz predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate AT zawadzkimarek predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate AT sosnowskiroman predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate AT tokarczykandrzej predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate AT poletajewsławomir predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate AT krystpiotr predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate AT nykłukasz predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate |